News
-
-
-
-
-
-
-
-
PRESS RELEASE
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Quantum BioPharma reports financial results for Q4 & FY 2024, highlights completion of unbuzzd clinical trial and Phase 1 of Lucid-21-302 multiple sclerosis drug, advancing pipeline of products -
-